Evidence map›Paper›PMID 32197410›Full record

ReviewInternational journal of molecular sciences2020

Potential Adverse Effects of Resveratrol: A Literature Review.

Abdullah Shaito, Anna Maria Posadino, Nadin Younes, Hiba Hasan, Sarah Halabi, Dalal Alhababi, Anjud Al-Mohannadi, Wael M Abdel-Rahman, Ali H Eid, Gheyath K Nasrallah and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 382 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
382citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

382 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The Effects of Resveratrol on Menopausal Cardio-metabolic Changes: A Systematic Review.Cardiovascular & hematological disorders drug targets · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

322 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abdullah ShaitoDepartment of Biological and Chemical Sciences, Lebanese International University, 1105 Beirut, Lebanon.ORCID 0000-0003-3524-7962
Anna Maria PosadinoDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.
Nadin YounesDepartment of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar.
Hiba HasanInstitute of Anatomy and Cell Biology, Justus-Liebig-University Giessen, 35392 Giessen, Germany.ORCID 0000-0001-5316-5480
Sarah HalabiBiology Department, Faculty of Arts and Sciences, American University of Beirut, 1105 Beirut, Lebanon.
Dalal AlhababiDepartment of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar.
Anjud Al-MohannadiDepartment of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar.
Wael M Abdel-RahmanDepartment of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O Box: 27272, United Arab Emirates.ORCID 0000-0002-2149-1043
Ali H EidDepartment of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, P.O. Box 11-0236 Beirut, Lebanon.
Gheyath K NasrallahDepartment of Biomedical Science, College of Health Sciences, and Biomedical Research Center Qatar University, P.O Box 2713 Doha, Qatar.ORCID 0000-0001-9252-1038
Gianfranco PintusDepartment of Medical Laboratory Sciences, College of Health Sciences and Sharjah Institute for Medical Research, University of Sharjah, Sharjah P.O Box: 27272, United Arab Emirates.ORCID 0000-0002-3031-7733

Funding

Qatar University IRCC#181
6 · The paper itself

Abstract

Due to its health benefits, resveratrol (RE) is one of the most researched natural polyphenols. Resveratrol's health benefits were first highlighted in the early 1990s in the French paradox study, which opened extensive research activity into this compound. Ever since, several pharmacological activities including antioxidant, anti-aging, anti-inflammatory, anti-cancerous, anti-diabetic, cardioprotective, and neuroprotective properties, were attributed to RE. However, results from the available human clinical trials were controversial concerning the protective effects of RE against diseases and their sequelae. The reason for these conflicting findings is varied but differences in the characteristics of the enrolled patients, RE doses used, and duration of RE supplementation were proposed, at least in part, as possible causes. In particular, the optimal RE dosage capable of maximizing its health benefits without raising toxicity issues remains an area of extensive research. In this context, while there is a consistent body of literature on the protective effects of RE against diseases, there are relatively few reports investigating its possible toxicity. Indeed, toxicity and adverse effects were reported following consumption of RE; therefore, extensive future studies on the long-term effects, as well as the in vivo adverse effects, of RE supplementation in humans are needed. Furthermore, data on the interactions of RE when combined with other therapies are still lacking, as well as results related to its absorption and bioavailability in the human body. In this review, we collect and summarize the available literature about RE toxicity and side effects. In this process, we analyze in vitro and in vivo studies that have addressed this stilbenoid. These studies suggest that RE still has an unexplored side. Finally, we discuss the new delivery methods that are being employed to overcome the low bioavailability of RE.

Indexed as

HumansResveratrolResveratrolanticancerantioxidant effectsbiphasicoxidative DNA damagepro-oxidant effectsreactive oxygen species (ROS)resveratrol

Identifiers

PMID32197410
PMCPMC7139620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.